Apixaban interacts with several drugs that can affect its efficacy and safety. For instance, potent inhibitors of CYP3A4 and P-glycoprotein, such as ketoconazole and ritonavir, can increase apixaban plasma concentrations, elevating the bleeding risk. Conversely, inducers like rifampin may decrease its effectiveness by reducing plasma levels. It is crucial to evaluate all concomitant medications to mitigate interaction risks.
